Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 26,000 shares of the stock in a transaction on Thursday, May 25th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $165,880.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $19,579,907.38. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, May 24th, Phillip Md Et Al Frost purchased 42,200 shares of Opko Health stock. The shares were acquired at an average price of $6.42 per share, with a total value of $270,924.00.
  • On Monday, May 22nd, Phillip Md Et Al Frost purchased 120,000 shares of Opko Health stock. The shares were acquired at an average price of $6.43 per share, with a total value of $771,600.00.
  • On Friday, May 19th, Phillip Md Et Al Frost purchased 9,200 shares of Opko Health stock. The shares were acquired at an average price of $6.60 per share, with a total value of $60,720.00.
  • On Thursday, May 18th, Phillip Md Et Al Frost purchased 20,000 shares of Opko Health stock. The shares were acquired at an average price of $6.59 per share, with a total value of $131,800.00.
  • On Wednesday, May 17th, Phillip Md Et Al Frost purchased 70,800 shares of Opko Health stock. The shares were acquired at an average price of $6.54 per share, with a total value of $463,032.00.
  • On Tuesday, May 16th, Phillip Md Et Al Frost purchased 27,800 shares of Opko Health stock. The shares were acquired at an average price of $6.61 per share, with a total value of $183,758.00.
  • On Wednesday, May 10th, Phillip Md Et Al Frost acquired 1,125,000 shares of Opko Health stock. The shares were purchased at an average cost of $6.96 per share, with a total value of $7,830,000.00.
  • On Monday, May 8th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The shares were purchased at an average cost of $7.22 per share, with a total value of $722,000.00.
  • On Friday, May 5th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were purchased at an average cost of $7.52 per share, with a total value of $75,200.00.
  • On Thursday, May 4th, Phillip Md Et Al Frost acquired 11,800 shares of Opko Health stock. The shares were purchased at an average cost of $7.51 per share, with a total value of $88,618.00.

Shares of Opko Health Inc. (NASDAQ:OPK) traded down 0.16% during trading on Friday, hitting $6.34. 372,934 shares of the stock were exchanged. The firm’s 50 day moving average price is $7.27 and its 200-day moving average price is $8.76. The stock’s market cap is $3.55 billion. Opko Health Inc. has a 52 week low of $6.31 and a 52 week high of $12.15.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.02. The firm had revenue of $296.10 million for the quarter, compared to the consensus estimate of $313.36 million. Opko Health had a negative net margin of 0.81% and a negative return on equity of 0.49%. The company’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.02) earnings per share. On average, analysts predict that Opko Health Inc. will post ($0.20) EPS for the current year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

ILLEGAL ACTIVITY NOTICE: “Insider Buying: Opko Health Inc. (OPK) CEO Buys 26,000 Shares of Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/26/insider-buying-opko-health-inc-opk-ceo-buys-26000-shares-of-stock.html.

A number of analysts recently weighed in on OPK shares. Guggenheim started coverage on shares of Opko Health in a report on Tuesday, March 14th. They issued a “buy” rating and a $25.00 price target for the company. Standpoint Research reaffirmed a “buy” rating and set a $14.00 target price on shares of Opko Health in a report on Sunday, March 5th. TheStreet lowered shares of Opko Health from a “c-” rating to a “d+” rating in a report on Wednesday, February 1st. Jefferies Group LLC lowered their target price on shares of Opko Health from $10.00 to $8.00 and set a “hold” rating for the company in a report on Thursday, March 2nd. Finally, Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, February 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $15.64.

Hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in shares of Opko Health during the fourth quarter worth about $105,000. Formidable Asset Management LLC increased its stake in Opko Health by 10.4% in the fourth quarter. Formidable Asset Management LLC now owns 11,638 shares of the biotechnology company’s stock worth $108,000 after buying an additional 1,096 shares in the last quarter. Timber Hill LLC acquired a new stake in Opko Health during the first quarter worth $114,000. Comerica Bank acquired a new stake in Opko Health during the fourth quarter worth $117,000. Finally, World Asset Management Inc increased its stake in Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,900 shares in the last quarter. 22.58% of the stock is currently owned by institutional investors and hedge funds.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

12 Month Chart for NASDAQ:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.